Netherlands Pharmaceuticals & Healthcare Report Q1 2013 - New Market Report Now Available
BMI View: While the Netherlands is a low-risk market from the point of view of multinational drugmakers, the country's modest per capita expenditure on pharmaceuticals relative to other Western European countries is an issue. Another challenge facing drugmakers is cost-containment, which will only intensify as the Netherlands enters a period of slower economic growth. In fact, as we warned, the Dutch authorities recently introduced a new scheme - reimbursement for medicines that prove therapeutically ineffective will be reclaimed from the...
View full press release